Pasar al contenido principal

MECANISMOS DE ACCION Y PROPIEDADES TERAPEUTICAS DE LOS LIGANDOS DE DREAM

SAF2014-53412-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2014
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Specific cytoarchitectureal changes in hippocampal subareas in daDREAM mice

  • Mellström, Britt
  • González, Paz
  • Dopazo, Xose M.
  • Naranjo, José Ramón
  • DeFelipe, Javier
Mellström, Britt et al., [Background] Transcriptional repressor DREAM (downstream regulatory element antagonist modulator) is a Ca2+-binding protein that regulates Ca2+ homeostasis through gene regulation and protein-protein interactions. It has been shown that a dominant active form (daDREAM) is implicated in learning-related synaptic plasticity such as LTP and LTD in the hippocampus. Neuronal spines are reported to play important roles in plasticity and memory. However, the possible role of DREAM in spine plasticity has not been reported., [Results] Here we show that potentiating DREAM activity, by overexpressing daDREAM, reduced dendritic basal arborization and spine density in CA1 pyramidal neurons and increased spine density in dendrites in dentate gyrus granule cells. These microanatomical changes are accompanied by significant modifications in the expression of specific genes encoding the cytoskeletal proteins Arc, Formin 1 and Gelsolin in daDREAM hippocampus., [Conclusions] Our results strongly suggest that DREAM plays an important role in structural plasticity in the hippocampus., This work was funded by Instituto de Salud Carlos III/CIBERNED (to JRN, BM and JdF), Madrid Community/Neurodegmodels (to JRN), by Ministerio de Economia y Competitividad (grants SAF2010-21784 and SAF2014-53412-R, to JRN) and by Areces Foundation, the EU 6th Framework Program: Network of Excellence NeuroNE (JRN) and the ERA-NET Programs Neuron (JRN), grants from the Medical Research Council (TVPB) and by grants from the EJLB-CIHR Michael Smith Chair in Neurosciences and Mental Health, Canada Research Chair, Canadian Institute for Health Research operating grant (MOP-124807), NSERC Discovery Grant (RGPIN 402555) (to MZ). SK had a postdoctoral contract from the Ramón y Cajal Program of the Ministry of Science and Innovation., We acknowledge support by the CSIC Open Access Publication Initiative through its Unit of Information Resources for Research (URICI)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Activating transcription factor 6 derepression mediates neuroprotection in Huntington disease

  • Naranjo, José Ramón
  • Villar, Diego
  • González Pérez, Paz
  • Dopazo, Xose M.
  • Morón-Oset, Javier
  • Higueras, Elena
  • Oliveros, Juan C.
  • Arrabal, María D.
  • Prieto, Ángela
  • Cercós, Pilar
  • González, Teresa
  • Cruz, Alicia de la
  • Casado-Vela, Juan
  • Rábano, Alberto
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
  • Mellström, Britt
Deregulated protein and Ca2+ homeostasis underlie synaptic dysfunction and neurodegeneration in Huntington disease (HD); however, the factors that disrupt homeostasis are not fully understood. Here, we determined that expression of downstream regulatory element antagonist modulator (DREAM), a multifunctional Ca2+-binding protein, is reduced in murine in vivo and in vitro HD models and in HD patients. DREAM downregulation was observed early after birth and was associated with endogenous neuroprotection. In the R6/2 mouse HD model, induced DREAM haplodeficiency or blockade of DREAM activity by chronic administration of the drug repaglinide delayed onset of motor dysfunction, reduced striatal atrophy, and prolonged life span. DREAM-related neuroprotection was linked to an interaction between DREAM and the unfolded protein response (UPR) sensor activating transcription factor 6 (ATF6). Repaglinide blocked this interaction and enhanced ATF6 processing and nuclear accumulation of transcriptionally active ATF6, improving prosurvival UPR function in striatal neurons. Together, our results identify a role for DREAM silencing in the activation of ATF6 signaling, which promotes early neuroprotection in HD., A. De la Cruz holds a RECAVA contract, A. Prieto and P. Cercós hold FPI fellowships, and T. González holds a Ramón y Cajal contract. J. Casado-Vela holds a JAE-DOC (CSIC) from the Spanish Ministerio de Economía y Competitividad (MINECO), cofunded by the European Social Fund. This work was funded by the Instituto de Salud Carlos III/CIBERNED (to J.R. Naranjo, B. Mellström, and A. Rábano), FISS-RIC RD12/0042/0019 (to C. Valenzuela), Madrid regional government/Neurodegmodels (to J.R. Naranjo), MINECO grants SAF2010-21784 and SAF2014-53412-R (to J.R. Naranjo), SAF2012-32209 (to M. Gutierrez-Rodriguez), SAF2010-14916 and SAF2013-45800-R (to C. Valenzuela), and a grant from the Swedish Research Council (J.Y. Li)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification of IQM-266, a novel DREAM ligand that modulates KV4 currents

  • Peraza, Diego A.
  • Cercós, Pilar
  • Miaja, Pablo
  • Merinero, Yaiza G.
  • Lagartera, Laura
  • Socuéllamos, Paula G.
  • Izquierdo García, Carolina
  • Sánchez, Sara A.
  • López-Hurtado, Alejandro
  • Martín-Martínez, Mercedes
  • Olivos-Oré, Luis Alcides
  • Naranjo, José Ramón
  • Artalejo, Antonio R.
  • Gutiérrez-Rodríguez, Marta
  • Valenzuela, Carmen
Downstream Regulatory Element Antagonist Modulator (DREAM)/KChIP3/calsenilin is a neuronal calcium sensor (NCS) with multiple functions, including the regulation of A-type outward potassium currents (I A). This effect is mediated by the interaction between DREAM and KV4 potassium channels and it has been shown that small molecules that bind to DREAM modify channel function. A-type outward potassium current (I A) is responsible of the fast repolarization of neuron action potentials and frequency of firing. Using surface plasmon resonance (SPR) assays and electrophysiological recordings of KV4.3/DREAM channels, we have identified IQM-266 as a DREAM ligand. IQM-266 inhibited the KV4.3/DREAM current in a concentration-, voltage-, and time-dependent-manner. By decreasing the peak current and slowing the inactivation kinetics, IQM-266 led to an increase in the transmembrane charge ( QKV4.3/DREAM ) at a certain range of concentrations. The slowing of the recovery process and the increase of the inactivation from the closed-state inactivation degree are consistent with a preferential binding of IQM-266 to a pre-activated closed state of KV4.3/DREAM channels. Finally, in rat dorsal root ganglion neurons, IQM-266 inhibited the peak amplitude and slowed the inactivation of I A. Overall, the results presented here identify IQM-266 as a new chemical tool that might allow a better understanding of DREAM physiological role as well as modulation of neuronal I A in pathological processes., PC was the recipient of a postgraduate FPI fellowship from the Spanish Ministry of Economy, Industry and Competitivity (MINECO). This work was funded by the Spanish Ministry of Economy, Industry and Competitivity (Ministerio de Economía y Competitividad; AEI-FEDER, EU grants): SAF2012-32209 and BFU2015-67284-R (to MG-R), SAF2014-53412-R and SAF2017- 89554-R (to JN), SAF2013-45800-R, SAF2016-75021-R (to CV) and SAF2015-66275-C2-2-R (to MM-M); Universidad Complutense de Madrid (UCM) grant: PR75/18-21593 (to AA); the Instituto de Salud Carlos III CIBERNED and CIBERCV programs (to JN and to CV, respectively) and the Madrid regional government/Neurodegmodels (to JN); Consejo Superior de Investigaciones Científicas (CSIC) grants: PIE 201820E104 (to CV) and 201880E109 (to MG-R and MM-M)., We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Identification of IQM-266, a novel DREAM ligand that modulates Kv4 currents

  • Peraza, Diego A.
  • Cercós, Pilar
  • Miaja, Pablo
  • Merinero, Yaiza G.
  • Lagartera, Laura
  • Socuéllamos, Paula G.
  • Izquierdo García, Carolina
  • Sánchez, Sara A.
  • López-Hurtado, Alejandro
  • Martín-Martínez, Mercedes
  • Olivos-Oré, Luis Alcides
  • Naranjo, José Ramón
  • Artalejo, Antonio R.
  • Gutiérrez-Rodríguez, Marta
  • Valenzuela, Carmen
Resumen del trabajo presentado al VII Congreso Red Española Canales Iónicos: Symposium 6: Drug Discovery and ion channel Pharmacology, celebrado en Cáceres del 15 al 17 de mayo de 2019., Funded by BFU2015-67284-R (to MG-R), SAF2014-53412-R and SAF2017-89554-R (to JN), SAF2013-45800-R, SAF2016-75021-R (to CV), SAF2015-66275-C2-2-R (to MM-M); UCM grant: PR75/18-21593 (to AA); and CSIC grants: PIE 201820E104 (to CV) and 201880E109 (to MG-R and MM-M)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Regulators of A20 (TNFAIP3): new drug-able targets in inflammation

  • Momtazi, G.
  • Lambrecht, N.
  • Naranjo, José Ramón
  • Schock, B. C.
Persistent activation of the transcription factor Nuclear factor-κB (NF-κB) is central to the pathogenesis of many inflammatory disorders, including those of the lung such as cystic fibrosis (CF), asthma, and chronic obstructive pulmonary disease (COPD). Despite recent advances in treatment, management of the inflammatory component of these diseases still remains suboptimal. A20 is an endogenous negative regulator of NF-κB signaling, which has been widely described in several autoimmune and inflammatory disorders and more recently in terms of chronic lung disorders. However, the underlying mechanism for the apparent lack of A20 in CF, COPD, and asthma has not been investigated. Transcriptional regulation of A20 is complex and requires coordination of different transcription factors. In this review we examine the existing body of research evidence on the regulation of A20, concentrating on pulmonary inflammation. Special focus is given to the repressor downstream regulatory element antagonist modulator (DREAM) and its nuclear and cytosolic action to regulate inflammation. We provide evidence that would suggest the A20-DREAM axis to be an important player in (airway) inflammatory responses and point to DREAM as a potential future therapeutic target for the modification of phenotypic changes in airway inflammatory disorders. A schematic summary describing the role of DREAM in inflammation with a focus on chronic lung diseases as well as the possible consequences of altered DREAM expression on immune responses is provided., B. C. Schock was supported by Northern Ireland Chest Heart and Stroke Grant NICHS-2014_15. J. R. Naranjo was funded by the Instituto de Salud Carlos III [Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED)], COST (BM1406), and AEI-FEDER, EU (SAF2014-53412-R and SAF2017-89554R).